50 completed, 8 terminated, 8 unknown, 7 recruiting. 87 Phase 2, 16 Phase 1, 10 Phase 3.
Follow Cytomegalovirus Infections: new trials by email Literature Review of Cytomegalovirus Infections trials Research Report on Cytomegalovirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II Valganciclovir, Ganciclovir (GCV), Placebo - Cytomegalovirus (CMV), Anterior Uveitis | Phase 2 | Not yet recruiting | University of California, San Francisco | 117 | 2026-11-01 | 2026-08-11 |
| Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections pathogen-specific CTLs - Pathogen Infection, EBV Infection | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-11-02 |
| ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse Valganciclovir, Placebo - Cytomegalovirus (CMV) Infection | Phase 2 | Not yet recruiting | Wits Health Consortium (Pty) Ltd | 130 | 2026-02-01 | 2026-01-30 |
| Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation. LB-DTK-MV - BKV Infection, EBV Infection | Phase 1 / Phase 2 | Recruiting | LucasBio | 27 | 2025-12-04 | 2026-06-26 |
| Study Evaluating the Efficacy and Safety of Artesunate Artesunate, Ganciclovir (GCV) - CMV Infection | Phase 2 | Recruiting | Amivas Inc. | 90 | 2025-08-01 | 2026-08-03 |
| Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes - Adenovirus, Cytomegalovirus Infections | Phase 1 / Phase 2 | Recruiting | Jessie L. Alexander | 25 | 2025-04-30 | 2025-08-14 |
| Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients Letermovir 480 MG [Prevymis] - Cytomegalovirus Infections, Transplant-Related Disorder | Phase 2 | Active not recruiting | University of Pennsylvania | 80 | 2024-04-04 | 2026-09-24 |
| A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 2 | Withdrawn | ModernaTX, Inc. | 2024-02-08 | 2024-03-15 | |
| Anti-viral T-cell Therapy by Gamma Capture Specific T- Lymphocytes - Adenovirus, Cytomegalovirus Infections | Phase 1 / Phase 2 | Enrolling by invitation | Paul Szabolcs | 25 | 2024-01-08 | 2026-06-29 |
| Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT Virus specific T cells - CMV Infection, EBV Infection | Phase 1 / Phase 2 | Unknown | Peking University People's Hospital | 29 | 2023-11-01 | 2023-10-10 |
| Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir. Letermovir 240 mg Oral Tablet - Infections, Cytomegalovirus | Phase 2 | Not yet recruiting | Maimónides Biomedical Research Institute of Córdoba | 90 | 2023-10-01 | 2023-09-28 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 2 | Active not recruiting | ModernaTX, Inc. | 84 | 2023-04-05 | 2026-08-10 |
| Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation. Cytotect®CP - Cytomegalovirus Infections | Phase 2 | Terminated | University Hospital, Lille | 2 | 2022-09-13 | 2025-09-30 |
| Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS Letermovir Pill - CMV Infection, Hematopoietic Stem Cell Transplantation | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 80 | 2022-07-07 | 2023-09-01 |
| Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Posoleucel (ALVR105), Placebo - Adenovirus Infection, BK Virus Infection | Phase 2 / Phase 3 | Terminated | AlloVir | 451 | 2022-03-24 | 2024-05-16 |
| Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection IFN-γ positive selected T-cells - Cytomegalovirus Infections | Phase 1 / Phase 2 | Withdrawn | Yae-Jean Kim | 2022-01-01 | 2020-03-20 | |
| Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection Cytotect - Kidney Transplantation, CMV Infection | Phase 2 | Completed | University Hospital, Bordeaux | 42 | 2021-11-17 | 2026-05-12 |
| Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) CMV-MVA Triplex, Placebo - Cytomegalovirus Infections, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 94 | 2021-11-02 | 2026-10-02 |
| A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine - Cytomegalovirus Infections | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 333 | 2021-10-14 | 2026-07-17 |
| A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection BCV - Adenovirus Infections, Cytomegalovirus Infection | Phase 2 | Completed | SymBio Pharmaceuticals | 53 | 2021-08-16 | 2026-08-11 |
Showing 20 of 87. Sign in to see all of them.
HIV Infections (15) · Acquired Immunodeficiency Syndrome (13) · Cytomegalovirus Retinitis (13) · Adenoviridae Infections (11) · Epstein-Barr Virus Infections (11) · AIDS-Related Opportunistic Infections (8) · Multiple Acyl Coenzyme A Dehydrogenase Deficiency (7) · Retinitis (6) · Virus Diseases (6) · DNA Virus Infections (4) · Hematologic Neoplasms (3) · Hodgkin Disease (3) · Lymphoma, Non-Hodgkin (3) · Myelodysplastic Syndromes (3)
Infections (86) · Herpesviridae Infections (85) · DNA Virus Infections (83) · Virus Diseases (81) · Immune System Diseases (24) · Immunologic Deficiency Syndromes (19) · Communicable Diseases (18) · Genital Diseases (18) · Sexually Transmitted Diseases (18) · Urogenital Diseases (18) · Blood-Borne Infections (17) · Lentivirus Infections (17) · RNA Virus Infections (17) · Retroviridae Infections (17) · Sexually Transmitted Diseases, Viral (17)
Valganciclovir (12) · Ganciclovir (9) · letermovir (6) · Foscarnet (5) · mRNA-1647 cytomegalovirus vaccine (4) · sevirumab (4) · Cidofovir (3) · Valacyclovir (3) · Therapeutics (2) · cytomegalovirus-specific hyperimmune globulin (2) · fomivirsen (2) · Acyclovir (1) · Alemtuzumab (1) · Antibodies, Monoclonal (1) · Antitubercular Agents (1)
National Institute of Allergy and Infectious Diseases (NIAID) (13) · ModernaTX, Inc. (4) · City of Hope Medical Center (3) · Peking University People's Hospital (3) · AlloVir (2) · Assistance Publique - Hôpitaux de Paris (2) · Ionis Pharmaceuticals, Inc. (2) · Johns Hopkins Bloomberg School of Public Health (2) · Memorial Sloan Kettering Cancer Center (2) · National Center for Research Resources (NCRR) (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · University Hospital, Bordeaux (2) · Agouron Pharmaceuticals (1) · Albert Park (1) · Amivas Inc. (1)
United States (52) · France (11) · United Kingdom (10) · Spain (7) · China (5) · Australia (4) · Germany (4) · Belgium (3) · Italy (3) · South Korea (3) · Austria (2) · Canada (2) · Israel (2) · Japan (2) · Mexico (2)
Jessie Alexander, MD (2) · MA Jacobson (2) · Ryotaro Nakamura, MD (2) · Albert Park, MD (1) · Amy C Sherman, MD (1) · Anna Pawlowska (1) · Betul Oran (1) · Borucki M (1) · Brosgart C (1) · C Crumpacker (1) · CS Crumpacker (1) · Cinta Moraleda, MD, PhD (1) · Collier AC (1)
PMID 31042791, PMID 38700045, PMID 10204198, PMID 11919489, PMID 12232843, PMID 12559647, PMID 15498605, PMID 17617198, PMID 18285548, PMID 19297572, PMID 21481708, PMID 24066743, PMID 24693891, PMID 26312852, PMID 27246524, PMID 27450392, PMID 27760761, PMID 27851688, PMID 27872061, PMID 29133549, PMID 30102389, PMID 31067570, PMID 32040960, PMID 32919517, PMID 33197929, PMID 35761406, PMID 36162011, PMID 36724434, PMID 38190492, PMID 38241643, PMID 38309519, PMID 38324766, PMID 38415855, PMID 38503664, PMID 38593233, PMID 38597860, PMID 39807668, PMID 40072882, PMID 40307889, PMID 40824644, PMID 40990374, PMID 41624481, PMID 42016921, PMID 42468541, PMID 9400786
2017 (3), 2005 (1), 2015 (1), 2018 (1), 2019 (1), 2023 (1), R01AI051355 (1), R01CA077544 (1), R01CA181045 (1), U01AI063565 (1), U01DC014706 (1), UG1EY036344 (1)